Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Saruparib |
Synonyms | |
Therapy Description |
AZD5305 inhibits PARP1, potentially inhibiting cell growth and inducing tumor regression (PMID: 35929986). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Saruparib | AZD 5305|AZD-5305|AZD5305 | PARP-1 Inhibitor 10 | Saruparib (AZD5305) inhibits PARP1, potentially leading to tumor growth inhibition (PMID: 35929986). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RAD51C del | ovarian cancer | sensitive | Saruparib | Preclinical - Cell culture | Actionable | In a preclinical study, Saruparib (AZD5305) inhibited colony formation in an ovarian cancer cell line with RAD51C deletion in culture (PMID: 35929986). | 35929986 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05938270 | Phase I | Darolutamide Darolutamide + Saruparib Saruparib | A Study to Investigate the Biological Effects of AZD5305, Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer. (ASCERTAIN) | Recruiting | USA | NLD | GBR | ESP | CAN | AUS | 0 |
NCT04644068 | Phase I | Carboplatin + Paclitaxel + Saruparib Paclitaxel + Saruparib Carboplatin + Saruparib Saruparib | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA) | Recruiting | USA | POL | ITA | HUN | GBR | ESP | CZE | CAN | AUS | 5 |